Pearson ADJ

Latest

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma
Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose
High Frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients
p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children's Cancer Study Group
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children′s Cancer Study Group
Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?
A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer
Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group Study
Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics
OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age
Cyclophosphamide metabolism in children with Fanconi's anaemia
The effect of fluconazole on cyclophosphamide metabolism in children
Cyclophosphamide pharmacokinetics in children
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation